ACOT5 activators comprise a diverse array of chemical compounds that enhance the functionality of ACOT5 through indirect engagement with various cellular metabolic pathways. Compounds such as AICAR, 5-Aminoimidazole-4-carboxamide ribonucleotide, and SRT1720 primarily target the AMP-activated protein kinase (AMPK) and SIRT1 pathways, respectively, which are central to cellular energy homeostasis. Activation of these pathways increases the catabolism of fatty acids, a process in which ACOT5 plays a crucial role by hydrolyzing acyl-CoA esters, thus potentially increasing its activity to meet the elevated metabolic demand. Furthermore, the activation of peroxisome proliferator-activated receptors (PPARs) by compounds like Bezafibrate, Fenofibrate, GW7647, WY-14643, Piroxicam, Gemfibrozil, and Pioglitazone leads to the upregulation of lipid metabolism. This upregulation islikely to enhance the enzymatic activity of ACOT5, given its function in the breakdown and turnover of fatty acid metabolites. These PPAR agonists converge on the β-oxidation pathway, where ACOT5's role in acyl-CoA ester hydrolysis is accentuated, thereby possibly increasing its functional activity to facilitate the efficient metabolism of lipids.
In addition to the PPAR pathway activators, compounds such as L-165041 and Oleoylethanolamide (OEA) also contribute to the augmentation of ACOT5 activity. L-165041, by activating PPARδ, and OEA through PPARα stimulation, both potentially enhance the fatty acid metabolism processes, which necessitates the hydrolytic activity of ACOT5 for maintaining cellular lipid homeostasis. The biochemical activation mechanisms of these ACOT5 activators are intricately linked to metabolic pathways that are essential for energy production and lipid turnover. Collectively, these compounds, by targeting pathways such as AMPK signaling and PPAR-mediated lipid metabolism, indirectly but significantly enhance the functional activity of ACOT5, ensuring that free fatty acid levels are maintained within the cell through efficient hydrolysis of acyl-CoA esters.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR stimulates AMP-activated protein kinase (AMPK) activity. When AMPK is activated, it may indirectly increase the activity of ACOT5 by enhancing fatty acid oxidation, where ACOT5 is implicated. | ||||||
Bezafibrate | 41859-67-0 | sc-204650B sc-204650 sc-204650A sc-204650C | 500 mg 1 g 5 g 10 g | $31.00 $46.00 $122.00 $204.00 | 5 | |
Bezafibrate acts as a PPAR agonist. Activation of PPARs can lead to upregulation of lipid metabolism pathways, possibly increasing the need for ACOT5's acyl-CoA thioesterase activity. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate, another PPARα agonist, may indirectly enhance ACOT5 activity by stimulating the peroxisomal β-oxidation pathway, for which ACOT5 provides necessary fatty acid substrates. | ||||||
GW 7647 | 265129-71-3 | sc-203068A sc-203068 sc-203068B sc-203068C | 1 mg 5 mg 10 mg 25 mg | $49.00 $170.00 $267.00 $661.00 | 6 | |
GW7647 is a potent PPARα agonist. It could indirectly increase ACOT5 activity by upregulating peroxisomal β-oxidation, which relies on acyl-CoA substrates that ACOT5 helps regulate. | ||||||
L-165041 | 79558-09-1 | sc-203094 | 5 mg | $156.00 | ||
L-165041 activates PPARδ receptors, potentially enhancing fatty acid metabolism processes that would require ACOT5's thioesterase activity to maintain free fatty acid levels within the cell. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
WY-14643 is a selective PPARα agonist, which could indirectly increase ACOT5 activity by stimulating lipid catabolism pathways where ACOT5 participates in the hydrolysis of acyl-CoA esters. | ||||||
Piroxicam | 36322-90-4 | sc-200576 sc-200576A | 1 g 5 g | $109.00 $376.00 | 2 | |
Piroxicam, traditionally an NSAID, can influence peroxisomal proliferator-activated receptors and may indirectly enhance ACOT5 activity by modulating lipid metabolism pathways. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Gemfibrozil, through its action as a PPARα agonist, may indirectly enhance ACOT5 by increasing the demand for its acyl-CoA thioesterase activity in lipid catabolism and energy production. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, a PPARγ agonist, indirectly augments ACOT5 activity through the enhancement of adipocyte differentiation and lipid storage processes, which ACOT5 may be involved in for lipid turnover. | ||||||
Oleylethanolamide | 111-58-0 | sc-201400 sc-201400A | 10 mg 50 mg | $90.00 $194.00 | 1 | |
OEA activates PPARα and can enhance satiety signals. This activation may indirectly stimulate ACOT5 activity by influencing lipid metabolism pathways that rely on acyl-CoA ester hydrolysis by ACOT5. | ||||||